fungizone intravenous injection
equity pharmaceutical (pty) ltd - injection - see ingredients - each 1,0 ml vial contains amphotericin b 50,0 mg
amphotericin b injectable, liposomal
sun pharmaceutical industries, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b liposome for injection is indicated for the following: - empirical therapy for presumed fungal infection in febrile, neutropenic patients. - treatment of cryptococcal meningitis in hiv infected patients (see description of clinical studies) . - treatment of patients with aspergillus species, candida species and/or cryptococcus species infections (see above for the treatment of cryptococcal meningitis) refractory to amphotericin b deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate. - treatment of visceral leishmaniasis. in immunocompromised patients with visceral leishmaniasis treated with amphotericin b liposome for injection, relapse rates were high following initial clearance of parasites (see description of clinical studies) . see dosage and administration for recommended doses by indication. amphotericin b liposome for injection is contraindicated in those patients who have demonstrated or have known hypersensiti
amphotericin b injection, powder, lyophilized, for solution
eugia us llc - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b liposome for injection is indicated for the following: - empirical therapy for presumed fungal infection in febrile, neutropenic patients. - treatment of cryptococcal meningitis in hiv-infected patients (see description of clinical studies ). - treatment of patients with aspergillus species, candida species and/or cryptococcus species infections (see above for the treatment of cryptococcal meningitis) refractory to amphotericin b deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate. - treatment of visceral leishmaniasis. in immunocompromised patients with visceral leishmaniasis treated with amphotericin b liposome for injection, relapse rates were high following initial clearance of parasites (see description of clinical studies ). see dosage and administration for recommended doses by indication. eleven clinical studies supporting the efficacy and safety of amphotericin b were conducted. this clinical program include
combivir
viiv healthcare pty ltd - zidovudine; lamivudine -
dbl vinblastine injection
hospira australia pty ltd - vinblastine sulfate -
lamivudine + zidovudine alphapharm
alphapharm pty ltd - zidovudine; lamivudine -
retrovir
viiv healthcare pty ltd - zidovudine -
trizivir
viiv healthcare pty ltd - zidovudine; lamivudine; abacavir sulfate -
valcyte
roche products pty ltd - valganciclovir -
lamivudine/zidovudine viatris 150/300
viatris limited - lamivudine 150mg; zidovudine 300mg - film coated tablet - active: lamivudine 150mg zidovudine 300mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white propylene glycol purified water sodium starch glycolate - indicated for the treatment of hiv infected adults and adolescents over the age of 12 years, with progressive immunodeficiency (cd4+ count = < 500 cells/mm³).